Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
Summary
This innovative breakthrough offers a promising solution for numerous difficult-to-drug targets, paving the way for significant advancements in drug discovery and development to address high unmet medical needs of patients.Non-degrading molecular glues were previously found serendipitously. Zhihua Yu, Founding Managing Parter of Lapam Capital added, By applying an innovative and well validated approach to effectively drug a broad spectrum of challenging or undruggable disease targets, Rapafusyn has the potential to address a major gap and unmet need in the pharma industry. Lapam Capital has a professional investment team with more than 20 years of international and domestic biopharmaceutical industry R&D and management experience and can provide comprehensive value-added support for the invested companies.Rapafusyn emerged from the laboratory of Dr. Jun O. Lius, Professor of Pharmacology and Molecular Sciences at Johns Hopkins University, with a mission to develop transformational medicines to address high unmet medical needs and enhance patient care. These compounds are rationally designed and engineered to bind FKBP and form a ternary complex with the disease target protein, offering a promising avenue for modulating intricate protein-protein interactions. RapaGluesTM frequently exhibit cell permeability directly from the starting point, enhancing their potential for therapeutic development.For more information, please visit rapafusyn.com or contact Heather Lavin: hlavin@rapafusyn.com